Technical Analysis for INZY - Inozyme Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -3.07% | |
| Pocket Pivot | Bullish Swing Setup | -3.07% | |
| Earnings Movers | Other | -3.07% | |
| Inside Day | Range Contraction | -3.07% | |
| Wide Bands | Range Expansion | -3.07% | |
| Gapped Up | Strength | -3.07% | |
| Oversold Stochastic | Weakness | -3.07% | |
| Death Cross | Bearish | 0.74% |
| Alert | Time |
|---|---|
| Down 2 % | about 5 hours ago |
| Jack-in-the-Box Bearish Entry | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| Down 1% | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.795 |
| 52 Week Low | 2.71 |
| Average Volume | 232,667 |
| 200-Day Moving Average | 5.20 |
| 50-Day Moving Average | 5.13 |
| 20-Day Moving Average | 4.81 |
| 10-Day Moving Average | 4.42 |
| Average True Range | 0.29 |
| RSI (14) | 31.97 |
| ADX | 18.36 |
| +DI | 16.19 |
| -DI | 30.04 |
| Chandelier Exit (Long, 3 ATRs) | 4.71 |
| Chandelier Exit (Short, 3 ATRs) | 4.90 |
| Upper Bollinger Bands | 5.70 |
| Lower Bollinger Band | 3.92 |
| Percent B (%b) | 0.1 |
| BandWidth | 37.17 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.21 |
| MACD Histogram | -0.076 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.50 | ||||
| Resistance 3 (R3) | 4.54 | 4.45 | 4.43 | ||
| Resistance 2 (R2) | 4.45 | 4.35 | 4.43 | 4.41 | |
| Resistance 1 (R1) | 4.28 | 4.29 | 4.23 | 4.23 | 4.39 |
| Pivot Point | 4.19 | 4.19 | 4.17 | 4.17 | 4.19 |
| Support 1 (S1) | 4.01 | 4.09 | 3.97 | 3.97 | 3.81 |
| Support 2 (S2) | 3.92 | 4.02 | 3.90 | 3.79 | |
| Support 3 (S3) | 3.75 | 3.92 | 3.77 | ||
| Support 4 (S4) | 3.70 |
